Price Alert

CureVac N.V. (CVAC)

NASDAQ: CVAC · Real-Time Price · USD

5.50

-0.01 (-0.18%)

At close: Aug 15, 2025, 2:32 PM

-0.18% (1D)

Bid	3.95
Market Cap	1.24B
Revenue (ttm)	523.7M
Net Income (ttm)	180.66M
EPS (ttm)	0.93
PE Ratio (ttm)	5.91
Forward PE	-10.67
Analyst	Hold

Ask	7.09
Volume	542,349
Avg. Volume (20D)	1,294,751
Open	5.48
Previous Close	5.51
Day's Range	5.48 - 5.54
52-Week Range	2.37 - 5.72
Beta	2.53

About CVAC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CVAC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CVAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

CureVac N.V. is scheduled to release its earnings on Aug 26, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+37.59%

CureVac shares are trading higher after BioNTech a... Unlock content with Pro Subscription

2 months ago

+10.59%

CureVac shares are trading higher following Q1 reported financial results.

News

50 minutes ago · accessnewswire.com

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acqui...

1 week ago · proactiveinvestors.co.uk

GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine tec...

1 week ago · reuters.com

CureVac settles patent dispute litigation with Pfizer and BioNTech

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

1 month ago · accessnewswire.com

CureVac Announces Voting Results of General Meeting

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on ...

1 month ago · zacks.com

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

2 months ago · investopedia.com

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow J...

2 months ago · schaeffersresearch.com

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

2 months ago · benzinga.com

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

2 months ago · proactiveinvestors.com

BioNTech boosts cancer mRNA pipeline with CureVac acquisition

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...

2 months ago · businesswire.com

CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter...

Load More News